Thus, TAAR1 agonism may be a novel therapeutic strategy for treating T2D and also shows potential for the pharmacotherapy of obesity from both drug- and diet-induced causes. The gene discussed is TAAR1; the disease is obesity due to melanocortin 4 receptor deficiency.